Middle East respiratory syndrome coronavirus infection CT: Difference between revisions
Joao Silva (talk | contribs) |
Joao Silva (talk | contribs) |
||
Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
[[MERS|Middle East Respiratory Syndrome]] ([[MERS]]) is a [[viral]] [[respiratory disease|respiratory illness]]. It is caused by an emerging [[coronavirus]], specifically a ''betacoronavirus'' called [[Middle east respiratory syndrome coronavirus|MERS-CoV]] ([[Middle east respiratory syndrome coronavirus|Middle East Respiratory Syndrome Coronavirus]]), first discovered in 2012. Being a relatively novel [[virus]], there is no [[virus]]-specific [[prevention]] or treatment options for [[MERS]] patients. Attending to the fact that a [[vaccine]] hasn't been developed yet, enhancing [[infection]] prevention and control measures is critical to prevent the possible spread of [[MERS-CoV]] in hospitals and communities. Persons with [[symptoms]] suspicious of [[MERS-CoV]] [[infection]] need medical evaluation. According to the [[CDC]], a ''confirmed case'' of [[MERS-CoV]] [[infection]] is considered an individual who shows laboratory confirmation of [[infection]] by [[MERS-CoV]]. This last one is given by a positive [[PCR]] test of ≥2 specific genomic targets or, a single positive target followed by successful sequencing of a second. On the contrary, a ''probable case'' of [[MERS-CoV]] [[infection]], is considered an individual under investigation who has missing or inconclusive laboratory test results for the [[infection]] and that has been in close contact with another individual who is a "laboratory-confirmed case" of [[MERS-CoV]] [[infection]].<ref name="pmid24841273">{{cite journal| author=Dyall J, Coleman CM, Hart BJ, Venkataraman T, Holbrook MR, Kindrachuk J et al.| title=Repurposing of clinically developed drugs for treatment of Middle East Respiratory Coronavirus Infection. | journal=Antimicrob Agents Chemother | year= 2014 | volume= | issue= | pages= | pmid=24841273 | doi=10.1128/AAC.03036-14 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24841273 }} </ref><ref name=WHO>{{cite web | title = Clinical management of severe acute respiratory infections when novel coronavirus is suspected: What to do and what not to do | url = http://www.who.int/csr/disease/coronavirus_infections/InterimGuidance_ClinicalManagement_NovelCoronavirus_11Feb13u.pdf }}</ref><ref name=CDC>{{cite web | title = MERS Prevention and Treatment | url = http://www.cdc.gov/coronavirus/MERS/about/prevention.html }}</ref><ref name=CDC case definitions>{{cite web | title = Middle East Respiratory Syndrome (MERS) | url = http://www.cdc.gov/coronavirus/mers/case-def.html }}</ref> | [[MERS|Middle East Respiratory Syndrome]] ([[MERS]]) is a [[viral]] [[respiratory disease|respiratory illness]]. It is caused by an emerging [[coronavirus]], specifically a ''betacoronavirus'' called [[Middle east respiratory syndrome coronavirus|MERS-CoV]] ([[Middle east respiratory syndrome coronavirus|Middle East Respiratory Syndrome Coronavirus]]), first discovered in 2012. Being a relatively novel [[virus]], there is no [[virus]]-specific [[prevention]] or treatment options for [[MERS]] patients. Attending to the fact that a [[vaccine]] hasn't been developed yet, enhancing [[infection]] prevention and control measures is critical to prevent the possible spread of [[MERS-CoV]] in hospitals and communities. Persons with [[symptoms]] suspicious of [[MERS-CoV]] [[infection]] need medical evaluation. According to the [[CDC]], a ''confirmed case'' of [[MERS-CoV]] [[infection]] is considered an individual who shows laboratory confirmation of [[infection]] by [[MERS-CoV]]. This last one is given by a positive [[PCR]] test of ≥2 specific [[genomic]] targets or, a single positive target followed by successful [[sequencing]] of a second. On the contrary, a ''probable case'' of [[MERS-CoV]] [[infection]], is considered an individual under investigation who has missing or inconclusive laboratory test results for the [[infection]] and that has been in close contact with another individual who is a "laboratory-confirmed case" of [[MERS-CoV]] [[infection]].<ref name="pmid24841273">{{cite journal| author=Dyall J, Coleman CM, Hart BJ, Venkataraman T, Holbrook MR, Kindrachuk J et al.| title=Repurposing of clinically developed drugs for treatment of Middle East Respiratory Coronavirus Infection. | journal=Antimicrob Agents Chemother | year= 2014 | volume= | issue= | pages= | pmid=24841273 | doi=10.1128/AAC.03036-14 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24841273 }} </ref><ref name=WHO>{{cite web | title = Clinical management of severe acute respiratory infections when novel coronavirus is suspected: What to do and what not to do | url = http://www.who.int/csr/disease/coronavirus_infections/InterimGuidance_ClinicalManagement_NovelCoronavirus_11Feb13u.pdf }}</ref><ref name=CDC>{{cite web | title = MERS Prevention and Treatment | url = http://www.cdc.gov/coronavirus/MERS/about/prevention.html }}</ref><ref name=CDC case definitions>{{cite web | title = Middle East Respiratory Syndrome (MERS) | url = http://www.cdc.gov/coronavirus/mers/case-def.html }}</ref> | ||
==CT== | ==CT== |
Revision as of 14:50, 20 June 2014
Middle East Respiratory Syndrome Coronavirus Infection Microchapters |
Differentiating Middle East Respiratory Syndrome Coronavirus Infection from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Middle East respiratory syndrome coronavirus infection CT On the Web |
American Roentgen Ray Society Images of Middle East respiratory syndrome coronavirus infection CT |
FDA on Middle East respiratory syndrome coronavirus infection CT |
CDC on Middle East respiratory syndrome coronavirus infection CT |
Middle East respiratory syndrome coronavirus infection CT in the news |
Blogs on Middle East respiratory syndrome coronavirus infection CT |
Directions to Hospitals Treating Middle East respiratory syndrome coronavirus infection |
Risk calculators and risk factors for Middle East respiratory syndrome coronavirus infection CT |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Middle East Respiratory Syndrome (MERS) is a viral respiratory illness. It is caused by an emerging coronavirus, specifically a betacoronavirus called MERS-CoV (Middle East Respiratory Syndrome Coronavirus), first discovered in 2012. Being a relatively novel virus, there is no virus-specific prevention or treatment options for MERS patients. Attending to the fact that a vaccine hasn't been developed yet, enhancing infection prevention and control measures is critical to prevent the possible spread of MERS-CoV in hospitals and communities. Persons with symptoms suspicious of MERS-CoV infection need medical evaluation. According to the CDC, a confirmed case of MERS-CoV infection is considered an individual who shows laboratory confirmation of infection by MERS-CoV. This last one is given by a positive PCR test of ≥2 specific genomic targets or, a single positive target followed by successful sequencing of a second. On the contrary, a probable case of MERS-CoV infection, is considered an individual under investigation who has missing or inconclusive laboratory test results for the infection and that has been in close contact with another individual who is a "laboratory-confirmed case" of MERS-CoV infection.[1][2][3]
CT
References
- ↑ Dyall J, Coleman CM, Hart BJ, Venkataraman T, Holbrook MR, Kindrachuk J; et al. (2014). "Repurposing of clinically developed drugs for treatment of Middle East Respiratory Coronavirus Infection". Antimicrob Agents Chemother. doi:10.1128/AAC.03036-14. PMID 24841273.
- ↑ "Clinical management of severe acute respiratory infections when novel coronavirus is suspected: What to do and what not to do" (PDF).
- ↑ "MERS Prevention and Treatment".